Q-omics provides the consensus-scored ZNF546 profile across patient tissues and cancer cell-line models. ZNF546 expression is associated with patient survival in 26 of 34 cancer types, with the highest sampling consensus in HNSC. Among the 18 cancer types available for tumor–normal comparison, ZNF546 is differentially expressed in 11, with the highest sampling consensus in THCA. Additionally, ZNF546 RNA expression shows 21,872 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight HNSC, THCA, and UVM as cancer lineages where ZNF546 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ZNF546 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ZNF546 survival associations across molecular data types. ZNF546 RNA expression shows survival associations in the most cancer types (26), followed by mutation status (7). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ZNF546 RNA expression–survival associations across cancer types. High ZNF546 expression shows unfavorable associations in UVM and KICH, but favorable associations in HNSC, BLCA, UCS and BRCA. The HNSC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify HNSC as the clearest survival context for ZNF546 RNA expression.
This table summarizes ZNF546 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11. The strongest signals are observed in THCA for RNA.
This table ranks reproducible tumor–normal expression differences for ZNF546. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ZNF546 shows lower tumor expression in THCA, UCEC, KICH and BRCA and higher tumor expression in KIRC and LIHC. The THCA box plot shows higher ZNF546 RNA expression in normal versus tumor tissue (log2 FC = −0.644, t-test p < 0.001).
This table shows molecular features associated with ZNF546 in patient tissues and cancer cell lines. In patient samples, ZNF546 shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, ZNF546 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_NSCLC_LUAD, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Myeloma and BLOOD_Leukemia.
